Some of them are feared to deteriorate the quality of FN management, such as the risk assessment of FN with the Multinational Association of Supportive Care in Cancer (MASCC) score at onset (Q2), administration of therapeutic G-CSF (Q11), and primary prophylactic G-CSF (ppG-CSF)(Q16) (Table 1, Supple Table). This evidence concerns the gene CSF3 and cancer.